Skip to content

Study · Case report or series · n = 3 · 2020

10 results

Dietary supplementation with L-carnosine improves patient-reported outcomes, autonomic nervous system performance, and brain metabolism in 3 adult patients with multiple sclerosis.

Zanini D, Jezdimirovic T, Stajer V, Ostojic J, Maksimovic N, Ostojic SM

Nutrition research (New York, N.Y.)30 Sept 2020Cited by 10 (Europe PMC)

PMID33189432 (opens in a new tab)DOI10.1016/j.nutres.2020.09.008 (opens in a new tab)PepBankPUB-33189432
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, symptom intensity diminished in 5 of 7 domains, 3 of 7 domains, and one domain across cases.

    In plain wordsIn patients with multiple sclerosis, symptom intensity decreased in several domains compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseMS symptom domains
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Overall treatment effect · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    domains with reduced symptom intensity
    5 of 7 domains
    CASE 1
    domains with reduced symptom intensity
    3 of 7 domains
    CASE 2
    domains with reduced symptom intensity
    1 domain
    CASE 3

    Source sentences

    Summary
    The intensity of symptoms and signs of MS after L-carnosine administration diminished in 5 out of 7 domains in CASE 1, in 3 out of 7 domains in CASE 2, and one domain in CASE 3; general fatigue was reduced in all 3 cases at the follow-up.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  2. 02HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, general fatigue decreased after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, fatigue decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseGeneral fatigue
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The intensity of symptoms and signs of MS after L-carnosine administration diminished in 5 out of 7 domains in CASE 1, in 3 out of 7 domains in CASE 2, and one domain in CASE 3; general fatigue was reduced in all 3 cases at the follow-up.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  3. 03HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, walking distance to exhaustion improved by 51.1%, 19.5%, and 2.1% across cases after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, walking distance increased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseWalking distance to exhaustion
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    walking distance to exhaustion improvement
    51.1%
    CASE 1
    walking distance to exhaustion improvement
    19.5%
    CASE 2
    walking distance to exhaustion improvement
    2.1%
    CASE 3

    Source sentences

    Summary
    This was accompanied by an improved walking distance to exhaustion in all patients, with values improved for 51.1% in CASE 1, 19.5% in CASE 2, and 2.1% in CASE 3 at 8-week follow-up.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  4. 04HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, parasympathetic modulation normalized after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, parasympathetic modulation normalized after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    Not applicableParasympathetic modulation
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Tests of autonomic cardiovascular reflexes demonstrate normalized parasympathetic modulation and balanced sympathetic function after L-carnosine intervention in all MS cases.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  5. 05HumanCase report or seriesEfficacy outcome

    In patients with multiple sclerosis, sympathetic function was balanced after L‑carnosine in all cases.

    In plain wordsIn patients with multiple sclerosis, sympathetic function became balanced after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    Not applicableSympathetic function
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Tests of autonomic cardiovascular reflexes demonstrate normalized parasympathetic modulation and balanced sympathetic function after L-carnosine intervention in all MS cases.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  6. 06HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, serum total antioxidant capacity increased by 4.6 to 49.6% after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, serum antioxidant capacity increased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseSerum total antioxidant capacity
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Inflammation markers · Whole body
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    serum total antioxidant capacity increase
    4.6 to 49.6%
    range across all patients

    Source sentences

    Summary
    An increase in serum total antioxidant capacity (TAC) was found at 8-week follow-up in all patients (from 4.6 to 49.6%); this was accompanied by lower blood lactate at post-administration in all cases (23.5% on average).
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  7. 07HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, blood lactate decreased by 23.5% on average after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, blood lactate decreased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    DecreaseBlood lactate
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Adipokines · Metabolic and weight
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    blood lactate decrease
    23.5%
    average across all cases

    Source sentences

    Summary
    An increase in serum total antioxidant capacity (TAC) was found at 8-week follow-up in all patients (from 4.6 to 49.6%); this was accompanied by lower blood lactate at post-administration in all cases (23.5% on average).
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  8. 08HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, brain choline-contained compounds increased by 18.9% on average after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, brain choline compounds increased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseBrain choline-contained compounds
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    brain choline-containing compounds increase
    18.9%
    average across all cases

    Source sentences

    Summary
    Single-voxel 1.5 T MR spectroscopy revealed increased brain choline-contained compounds (18.9% on average), total creatine (21.2%), and myo-inositol levels (12.3%) in girus cinguli at 8-week follow-up in all MS cases.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  9. 09HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, brain total creatine increased by 21.2% after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, brain total creatine increased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseBrain total creatine
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    brain total creatine increase
    21.2%
    all MS cases, gyrus cinguli

    Source sentences

    Summary
    Single-voxel 1.5 T MR spectroscopy revealed increased brain choline-contained compounds (18.9% on average), total creatine (21.2%), and myo-inositol levels (12.3%) in girus cinguli at 8-week follow-up in all MS cases.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.
  10. 10HumanCase report or seriesActivity measurement

    In patients with multiple sclerosis, brain myo-inositol increased by 12.3% after L‑carnosine.

    In plain wordsIn patients with multiple sclerosis, brain myo-inositol increased after L‑carnosine compared with baseline.

    Peptide
    L-carnosine
    Outcome
    IncreaseBrain myo-inositol
    Study

    n = 3

    Comparator
    Baseline
    Outcome group
    Metabolic pathways and metabolomics · Nervous system and cognition
    Studied dose
    2 g/day · oral · 8 weeksAs given in this study (human).

    Measurements

    brain myo-inositol increase
    12.3%
    all MS cases, gyrus cinguli

    Source sentences

    Summary
    Single-voxel 1.5 T MR spectroscopy revealed increased brain choline-contained compounds (18.9% on average), total creatine (21.2%), and myo-inositol levels (12.3%) in girus cinguli at 8-week follow-up in all MS cases.
    1 context sentence
    Summary · context
    L-carnosine (2 g/day) was administered orally for 8 weeks in 2 women and one man suffering from MS.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.